Al Robichaud

Al Robichaud

Private Equity Investor at Cure Ventures Management LP

Net worth: 3 M $ as of 2024-03-30

63 year
Consumer Services
Health Technology
Commercial Services

Profile

Currently, Albert J. Robichaud is Chief Scientific Officer of SAGE Therapeutics, Inc. Dr. Robichaud previously held the position of VP-Chemistry & Pharmacokinetic Sciences at Lundbeck USA Inc., VP-Chemistry & Pharmacokinetic Sciences at Lundbeck, Inc. and Senior Director & Head-Neuroscience Discovery at Wyeth Research. Albert J. Robichaud received an undergraduate degree from Rensselaer Polytechnic Institute and a doctorate from the University of California, Irvine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2023-02-12 145,553 ( 0.24% ) 3 M $ 2024-03-30

Al Robichaud active positions

CompaniesPositionStart
Private Equity Investor 2023-12-31
All active positions of Al Robichaud

Former positions of Al Robichaud

CompaniesPositionEnd
SAGE THERAPEUTICS, INC. Chief Tech/Sci/R&D Officer 2023-10-08
Corporate Officer/Principal 2010-12-31
Director/Board Member 2009-12-31
Lundbeck USA Inc. Corporate Officer/Principal -
See the detail of Al Robichaud's experience

Training of Al Robichaud

Rensselaer Polytechnic Institute Undergraduate Degree
University of California, Irvine Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Al Robichaud's experience

Connections

60

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
SAGE THERAPEUTICS, INC.

Health Technology

Private companies4

Commercial Services

Health Technology

Lundbeck USA Inc.

Finance

See company connections